The CDC, in collaboration with state and local health departments, is investigating reports of serious adverse events, including deaths, following receipt of injectable ceftriaxone (brand names Ceftrisol Plus® and Rocephin®). The Kentucky Department for Public Health (KDPH) was also recently notified by two healthcare facilities in Kentucky about medical events associated with administration of ceftriaxone.
Due to the possibility that additional adverse events have occurred in Kentucky or might still be occurring, KDPH is actively seeking reports of severe adverse reactions associated with ceftriaxone administration or reconstitution issues.
Specific ceftriaxone-related adverse events for which we are seeking reports include: death, life-threatening outcomes, hospitalization (initial or prolonged), outcomes which required intervention to prevent permanent impairment or damage, or other serious medical events (not usual or minor reactions to ceftriaxone administration).
If you have medical documentation of an event that fits any of the categories described above, between October 1, 2024 to the present, KDPH asks that you report that event. You can do this by sending an email to Michael Curran at michael.curran@ky.gov, with the Subject heading “Ceftriaxone Reaction Report.” KDPH will contact you to gather additional information.
KDPH also recommends submitting a report to FDA’s MedWatch on any adverse event that might be related to a pharmaceutical or other medication using Form FDA 3500 found on FDA’s MedWatch website.
Please see the KDPH Notification and Call for Cases for additional details.
